Status:
ENROLLING_BY_INVITATION
Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Penile Cancer, Recurrent
Eligibility:
MALE
18+ years
Brief Summary
The treatment paradigm for primary penile squamous cell carcinoma (PSCC) has increasingly favored maximal organ preservation without compromising oncological outcomes. However, the literature has ofte...
Detailed Description
Penile squamous cell carcinoma (PSCC) is a rare disease with a limited body of evidence on which to base management decisions. The World Health Organization (WHO) has estimated 36,068 new cases of pen...
Eligibility Criteria
Inclusion
- Age over 18 years.
- Underwent low-risk OSS defined as: wide local excision, partial glansectomy, laser ablation, circumcision, and glans resurfacing for PSCC
Exclusion
- Underwent partial or total penectomy as primary surgery
- regional lymph node involvement at presentation (cN+ stage)
- metastates at presentation (cM+ stage)
Key Trial Info
Start Date :
June 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06565585
Start Date
June 3 2024
End Date
June 1 2025
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospitals Leuven
Leuven, Belgium, 3000